{"id":"leuprolide-acetate-3-month-depot","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Hot flashes"},{"rate":"10–20","effect":"Injection site reaction"},{"rate":"40–60","effect":"Decreased libido"},{"rate":"30–50","effect":"Erectile dysfunction"},{"rate":"5–15","effect":"Headache"},{"rate":"10–20","effect":"Fatigue"},{"rate":"5–10","effect":"Gynecomastia"},{"rate":null,"effect":"Bone density loss (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1200775","moleculeType":"Protein","molecularWeight":"1269.47"},"_fixedAt":"2026-03-30T11:57:27.081495","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in castration-level testosterone suppression in males and estrogen suppression in females, making it effective for hormone-dependent conditions. The 3-month depot formulation provides sustained drug release over 12 weeks via intramuscular injection.","oneSentence":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:42.816Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids (leiomyomata)"},{"name":"Central precocious puberty"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06654336","phase":"PHASE2","title":"Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)","status":"RECRUITING","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2026-03-30","conditions":"Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer","enrollment":162},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT02274779","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-08-20","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT03902951","phase":"PHASE2","title":"Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-03-17","conditions":"Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma","enrollment":28},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT00544830","phase":"PHASE2","title":"Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-18","conditions":"PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":29},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT00687739","phase":"PHASE3","title":"Prevention of Obesity in Women Via Estradiol Regulation","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-05","conditions":"Obesity","enrollment":79},{"nctId":"NCT05169112","phase":"PHASE3","title":"Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT06855589","phase":"PHASE3","title":"Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2025-03","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":400},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":"Endometriosis Ovary","enrollment":80},{"nctId":"NCT03035032","phase":"PHASE4","title":"A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2017-06-23","conditions":"Prostate Cancer","enrollment":107},{"nctId":"NCT01194271","phase":"PHASE2","title":"Neoadjuvant Ipilimumab in Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT05568940","phase":"","title":"Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-09","conditions":"Endometriosis, Fibroids","enrollment":""},{"nctId":"NCT03695237","phase":"PHASE3","title":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-24","conditions":"Central Precocious Puberty (CPP)","enrollment":45},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT05574712","phase":"PHASE2","title":"A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-01-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02203331","phase":"PHASE2","title":"Bay98-7196, Dose Finding / POC Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-16","conditions":"Endometriosis","enrollment":319},{"nctId":"NCT04914195","phase":"PHASE3","title":"Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Bharat Serums and Vaccines Limited","startDate":"2021-07-01","conditions":"Advanced Prostate Adenocarcinoma","enrollment":155},{"nctId":"NCT03845751","phase":"PHASE2","title":"EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.","status":"UNKNOWN","sponsor":"Institut Mutualiste Montsouris","startDate":"2023-01","conditions":"Prostate Cancer, Androgen Deprivation Therapy","enrollment":20},{"nctId":"NCT04239599","phase":"NA","title":"Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2011-03-31","conditions":"Prostate Cancer","enrollment":178},{"nctId":"NCT04225221","phase":"PHASE2","title":"Neurobiology of Bulimia Nervosa","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-02-24","conditions":"Bulimia Nervosa","enrollment":10},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT05304169","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","startDate":"2017-11-14","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT02807363","phase":"PHASE2","title":"A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Enteris BioPharma Inc.","startDate":"2017-08-23","conditions":"Endometriosis","enrollment":35},{"nctId":"NCT03085095","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":1134},{"nctId":"NCT02508636","phase":"PHASE2","title":"Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2015-12-22","conditions":"Prostatic Neoplasms, Pelvic Nodal","enrollment":11},{"nctId":"NCT03396978","phase":"NA","title":"The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2018-01-11","conditions":"Adipose Tissue, Microbiome, Menopause","enrollment":5},{"nctId":"NCT00621179","phase":"PHASE4","title":"Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF","status":"COMPLETED","sponsor":"Colorado Center for Reproductive Medicine","startDate":"2003-03","conditions":"Endometriosis, Infertility","enrollment":37},{"nctId":"NCT04891731","phase":"","title":"Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-05","conditions":"Hormone Receptor-positive Breast Cancer","enrollment":120},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT04500743","phase":"NA","title":"Role of Suppression of Endometriosis With Progestins Before IVF-ET","status":"COMPLETED","sponsor":"National Research Centre, Egypt","startDate":"2018-08-01","conditions":"IVF, Endometriosis, Pregnancy Rate","enrollment":134},{"nctId":"NCT02168062","phase":"PHASE2","title":"Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-06-16","conditions":"Prostate Adenocarcinoma","enrollment":57},{"nctId":"NCT02811809","phase":"PHASE2","title":"Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00937768","phase":"PHASE2","title":"Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2009-07","conditions":"Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer","enrollment":16},{"nctId":"NCT00582556","phase":"PHASE2","title":"Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-04","conditions":"Prostate Cancer","enrollment":44},{"nctId":"NCT00254397","phase":"PHASE2","title":"Melanoma Vaccine With Peptides and Leuprolide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-11","conditions":"Melanoma","enrollment":98},{"nctId":"NCT02057939","phase":"PHASE2","title":"Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-04","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT03078829","phase":"","title":"The Relation of GnRH Treatment to QTc Interval in Transgender Females","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-05-01","conditions":"Gender Dysphoria","enrollment":3},{"nctId":"NCT01136226","phase":"PHASE4","title":"Evaluate Recovery of Testosterone for Patients Using Eligard","status":"COMPLETED","sponsor":"Chesapeake Urology Research Associates","startDate":"2003-10","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT02689921","phase":"PHASE2","title":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","status":"UNKNOWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-04","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT00223665","phase":"PHASE2","title":"Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"1997-01-08","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT01120236","phase":"PHASE2","title":"Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer","enrollment":211},{"nctId":"NCT02736435","phase":"PHASE3","title":"Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound","status":"WITHDRAWN","sponsor":"Thunder Bay Regional Health Research Institute","startDate":"2018-01-18","conditions":"Uterine Leiomyoma","enrollment":""},{"nctId":"NCT00193856","phase":"PHASE3","title":"RADAR Trial - Randomised Androgen Deprivation and Radiotherapy","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-10","conditions":"Prostate Cancer","enrollment":1071},{"nctId":"NCT00225420","phase":"PHASE1, PHASE2","title":"Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-08","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT01642732","phase":"PHASE1","title":"Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2012-10","conditions":"Prostate Cancer","enrollment":1},{"nctId":"NCT01431391","phase":"PHASE2","title":"Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2011-09","conditions":"Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma","enrollment":68},{"nctId":"NCT00170157","phase":"PHASE2","title":"Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-06","conditions":"Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":112},{"nctId":"NCT01415960","phase":"PHASE3","title":"Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer","status":"COMPLETED","sponsor":"GP-Pharm","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":163},{"nctId":"NCT00928434","phase":"PHASE3","title":"A Study of Degarelix in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-05","conditions":"Prostate Cancer","enrollment":409},{"nctId":"NCT02361905","phase":"PHASE4","title":"Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas","status":"UNKNOWN","sponsor":"University Magna Graecia","startDate":"2015-02","conditions":"Fibroid","enrollment":42},{"nctId":"NCT02361879","phase":"PHASE4","title":"Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma","status":"UNKNOWN","sponsor":"University Magna Graecia","startDate":"2015-02","conditions":"Fibroid","enrollment":146},{"nctId":"NCT02357563","phase":"PHASE4","title":"Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation","status":"UNKNOWN","sponsor":"University Magna Graecia","startDate":"2015-02","conditions":"Fibroid","enrollment":110},{"nctId":"NCT00521781","phase":"PHASE2","title":"Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-08","conditions":"Prostatic Neoplasms","enrollment":14},{"nctId":"NCT01603420","phase":"PHASE2, PHASE3","title":"External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer","status":"TERMINATED","sponsor":"Proton Collaborative Group","startDate":"2012-07","conditions":"Prostate Cancer","enrollment":2},{"nctId":"NCT00949962","phase":"PHASE3","title":"Post-operative or Early Salvage XRT and ADT for High Risk PCa","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2009-10","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT00378690","phase":"PHASE3","title":"A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-03","conditions":"Prostate Cancer","enrollment":706},{"nctId":"NCT00667446","phase":"PHASE3","title":"Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-12","conditions":"Precocious, Leuprolide Acetate, Luteinizing Hormone (LH)","enrollment":72},{"nctId":"NCT00514917","phase":"PHASE3","title":"A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Prostatic Neoplasms","enrollment":413},{"nctId":"NCT00429494","phase":"PHASE2","title":"GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Amenorrhea, Premature Ovarian Failure, Ovarian Function Insufficiency","enrollment":60},{"nctId":"NCT00451958","phase":"PHASE3","title":"A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":386},{"nctId":"NCT01344564","phase":"NA","title":"Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide","status":"COMPLETED","sponsor":"Urology of Virginia","startDate":"2011-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT00512668","phase":"PHASE1","title":"Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":24},{"nctId":"NCT00283062","phase":"PHASE3","title":"Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-12","conditions":"Prostatic Neoplasms","enrollment":228},{"nctId":"NCT01078545","phase":"","title":"Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-09","conditions":"Advanced Prostate Cancer, Lower Urinary Tract Symptoms","enrollment":729},{"nctId":"NCT00635817","phase":"PHASE3","title":"A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-06","conditions":"Puberty, Precocious","enrollment":84},{"nctId":"NCT00626431","phase":"PHASE3","title":"A Study of Leuprolide to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":310},{"nctId":"NCT00630799","phase":"PHASE3","title":"Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients","status":"TERMINATED","sponsor":"GP-Pharm","startDate":"2008-05","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00776074","phase":"PHASE2","title":"A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-06","conditions":"Uterine Fibroids","enrollment":80},{"nctId":"NCT00275262","phase":"PHASE2","title":"A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation","status":"TERMINATED","sponsor":"Abbott","startDate":"2006-02","conditions":"Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2026 Mar 13","pmid":"41824265","title":"Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification.","journal":"Paediatric drugs"},{"date":"2014 Sep","pmid":"24926950","title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.","journal":"The Journal of clinical endocrinology and metabolism"},{"date":"2014 Jul","pmid":"24756362","title":"Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.","journal":"Clinical drug investigation"},{"date":"2012 May","pmid":"22344198","title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.","journal":"The Journal of clinical endocrinology and metabolism"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-818","Lupron","Leuprorelin acetate"],"phase":"phase_3","status":"active","brandName":"Leuprolide Acetate 3 Month Depot","genericName":"Leuprolide Acetate 3 Month Depot","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids (leiomyomata).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}